Search - tctmd.com

Displaying 101 - 120 of 133

Sort: Relevancy | Date

Presentation Fellows 2015

Antithrombin Pharmacology for the Interventionalist

Presenter: Manish A. Parikh, Roxana Mehran, David J. Cohen

May 15, 2015

Presentation TCT 2014

TCT 347: Assessment of Intravascular Ultrasound-Derived Minimal Lumen Area and Fractional Flow Reserve to Evaluate Functionally Significant Coronary Artery Disease: A Meta-analysis

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Jae-Sik Jang, MD

September 13, 2014

Presentation TCT 2014

TCT 252: Preprocedural Statin Administration Benefit According to Baseline Renal Function: A Meta-analysis of Randomized Controlled Trials

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Daniele Giacoppo, MD

September 13, 2014

Presentation TCT 2014

Meta-analysis: From PRISMA Standards to Utility in Guiding Practice

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Definition, Reliability, and Interpretation of Surrogate Endpoints

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen

September 13, 2014

Presentation TCT 2014

Subgroup Analyses: Proceed (and Interpret) with Caution

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Eugene H. Blackstone

September 13, 2014

Presentation TCT 2014

Randomized vs Observational Studies: Strengths and Weaknesses

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen

September 13, 2014

Presentation TCT 2014

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Patrick W. Serruys, David J. Cohen, Axel Linke

September 13, 2014

Presentation TCT 2014

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen, Matthew R. Reynolds

September 13, 2014

Presentation TCT 2014

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen, Samir R. Kapadia

September 13, 2014

Presentation

Cost-Effectiveness of PCI with DES vs Bypass Surgery for Patients with 3-Vessel or Left Main CAD

Presenter: David J. Cohen

August 11, 2014

Presentation TVT 2014

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Presenter: David J. Cohen

June 07, 2014

Presentation Fellows 2014

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: David Cohen

April 12, 2014

Presentation

The Cost of TAVR: Where Can We Save?

Presenter: David Cohen

October 29, 2013

Presentation TCT 2013

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

Presenter: David Cohen

October 29, 2013

Presentation TCT 2013

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presenter: David Cohen

October 28, 2013

Presentation TVT 2013

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

Presenter: David Cohen

June 13, 2013

Advertisement

Antithrombin Pharmacology for the Interventionalist

TCT 347: Assessment of Intravascular Ultrasound-Derived Minimal Lumen Area and Fractional Flow Reserve to Evaluate Functionally Significant Coronary Artery Disease: A Meta-analysis

TCT 252: Preprocedural Statin Administration Benefit According to Baseline Renal Function: A Meta-analysis of Randomized Controlled Trials

Meta-analysis: From PRISMA Standards to Utility in Guiding Practice

Definition, Reliability, and Interpretation of Surrogate Endpoints

Subgroup Analyses: Proceed (and Interpret) with Caution

Randomized vs Observational Studies: Strengths and Weaknesses

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis

Cost-Effectiveness of PCI with DES vs Bypass Surgery for Patients with 3-Vessel or Left Main CAD

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

The Cost of TAVR: Where Can We Save?

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content